Evommune reports EVO756 Phase 2b misses primary endpoint; halts CSU development

Evommune announced EVO756 Phase 2b in chronic spontaneous urticaria did not meet the primary endpoint and the company will cease development in CSU.Key Highlights:Original SEC Filing: Evommune, Inc. [ EVMN ] - 8-K - Jun. 29, 2026This is an AI-powered summary. It may contain inaccuracies. Consider v…

Evommune announced EVO756 Phase 2b in chronic spontaneous urticaria did not meet the primary endpoint and the company will cease development in CSU.

Key Highlights:

Phase 2b randomized, double-blind, placebo-controlled trial (n=160) failed to meet primary endpoint: mean change in UAS7 at 12 weeks.
Trial enrolled antihistamine-refractory moderate-to-severe CSU patients across US, Europe, Canada and Japan; three active doses vs placebo tested.
Evommune will stop development of EVO756 for CSU but will continue evaluating EVO756 in other indications.
Company reports EVO756 doses were safe and well tolerated and plans ongoing Phase 2b work in atopic dermatitis and initiated screening for migraine prophylaxis.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.